Why this matters
- The sodium-glucose co-transporter 2 (SGLT2) inhibitor has already been linked to reduced HF hospitalisation risk in patients with diabetes.
- 16.3% taking dapagliflozin vs 21.2% taking placebo had the composite primary outcome of worsening HF or cardiovascular death.
- HR, 0.74 (95% CI, 0.65-0.85).
- Separately, 10.0% taking dapagliflozin vs 13.7% taking placebo had a worsening HF event.
- HR, 0.70 (95% CI, 0.59-0.83).
- Cardiovascular death occurred in 9.6% taking dapagliflozin vs 11.5% taking placebo.
- HR, 0.82 (95% CI, 0.69-0.98).
- Any-cause death occurred in 11.6% taking dapagliflozin vs 13.9% taking placebo.
- HR, 0.83 (95% CI, 0.71-0.97).
- Findings were similar between patients with and without diabetes.
- Adverse event frequency was similar between the groups.
- Phase 3, placebo-controlled trial including 4744 participants with HF, ejection fraction ≤40%.
- Drug dose, 10 mg/day.
- Just under half of the patients in each group had diabetes.
- Funding: AstraZeneca.
- Generalisability of selected clinical trial population results not known.
- Few black participants.